Therapeutic Solutions Announces Universal Donor Myeloid Derived Suppressor Therapy Platform for Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Rhea-AI Summary

Breathe Biologics, a subsidiary of TSOI, has announced promising data regarding a novel cellular therapy targeting Chronic Obstructive Pulmonary Disease (COPD). Research indicates that monocytic progenitors from umbilical cord blood can reduce inflammation and enhance lung function in animal models. The therapy’s efficacy was linked to the blockade of certain cytokines, suggesting a potential mechanism of action. Breathe Biologics plans to utilize JadiCells, currently in Phase III for COVID ARDS, for COPD treatment under IND# 28508. The collaboration highlights the innovation environment in the USA.

Positive

• New promising data for COPD treatment through a novel cellular therapy.
• Monocytic progenitors showed a reduction in inflammation and preservation of lung function in animal models.
• Acquisition of IND# 28508 for JadiCells, enhancing potential for clinical development.

Negative

• None.

Breathe Biologics Inc., a Pulmonary Regenerative Medicine Subsidiary of TSOI, Discloses Allogeneic Pulmonary Myeloid Suppressor Cell Based Product

ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International (TSOI) announced today new data, licensing, and patent filing on a novel cellular therapy for treatment of Chronic Obstructive Pulmonary Disease (COPD) by its Spin-Off Company Breathe Biologics.

The Company disclosed that administration of monocytic progenitors derived from umbilical cord blood treated under proprietary conditions were able to reduce inflammation and preserve lung function in the elastase mediated animal model of COPD. The cellular product possessed characteristics of pulmonary progenitor cells combined with immune regulatory myeloid suppressor cells.

Furthermore, it was demonstrated that blockade of the cytokine’s interleukin-10 and/or interleukin-17 negated the therapeutic effect of the cells, thus suggesting a possible mechanism of action for this novel cellular therapy.

“As a physician who has witnessed firsthand the dismal lack of options in treatment of advanced COPD, and based on our preclinical animal data, I am eager to work with regulators in accelerating translation from the bench to the clinic,” said Dr. James Veltmeyer, Chief Medical Officer and co-inventor of the patent.

Breathe Biologics is developing the use of JadiCells, a stem cell product in Phase III for COVID ARDS, for the treatment of COPD under IND# 28508. Breathe Biologics has acquired the IND from Therapeutic Solutions International as part of its initial licensing.

“The beauty of running a biotechnology company in the USA is that we have access to brilliant minds, we have access to a patent system that respects innovation, we have access to collaborators who can perform experiments for us in a rapid and efficient manner, and we have investors and regulators who assess our work in real-time,” said Timothy Dixon, President, and CEO of Therapeutic Solutions International and co-inventor.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005599/en/

Timothy G. Dixon

ir@tsoimail.com

Source: Therapeutic Solutions International

FAQ

What new data has TSOI released regarding COPD treatment?

TSOI's subsidiary, Breathe Biologics, disclosed data showing that monocytic progenitors derived from umbilical cord blood can reduce inflammation and preserve lung function in COPD animal models.

What is the significance of the cytokine blockade in TSOI's new therapy?

The blockade of interleukin-10 and interleukin-17 negated the therapeutic effect, indicating a potential mechanism of action for the new cellular therapy.

How is JadiCells linked to the treatment for COPD?

JadiCells, a stem cell product in Phase III for COVID ARDS, will be utilized by Breathe Biologics for treating COPD under IND# 28508.

What does TSOI aim to achieve with their new cellular therapy?

TSOI aims to accelerate the clinical translation of their novel therapy for COPD, addressing the lack of treatment options.